CRCT
Cricut, Inc.
CRCT's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over CRCT overall, supported by stronger modeled upside and stronger valuation.
CRCT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
CRCT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CRCT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.15 | -28% |
| Current | 19x | $8.50 | — |
| Fair | 21x | $9.29 | +9.3% |
| Forward | 30x | $8.50 | — |
| Expensive | 34x | $15.24 | +79% |
Historical ranges are pointers, not guarantees.
CRCT's PE is in its fair range at 19x. On analysts' estimates for next year's earnings, today's price would be 30x, in its expensive range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over CRCT in the historical PE scenario, which offers more potential upside but is not a forecast.
CRCT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CRCT, with profitability improving.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | -38% |
| Q3 2026 | $0.45 | +18% |
| Q2 2026 | $0.42 | +27% |
| Q1 2026 | $0.34 | +9.7% |
| Q4 2025 | $0.35 | +21% |
| Q3 2025 | $0.38 | +36% |
| Q2 2025 | $0.33 | +6.5% |
| Q1 2025 | $0.31 | +6.9% |
| Q4 2024 | $0.29 | +21% |
CRCT's earnings per share have fallen from their peak: $0.45 over the past year, against $0.95 in mid-2021.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CRCT on earnings, with stronger typical year-over-year growth.
CRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $188.6M | +11% |
| Q2 2026 | $156.3M | -9.2% |
| Q1 2026 | $159.5M | -1.9% |
| Q4 2025 | $203.6M | -2.7% |
| Q3 2025 | $170.4M | +1.5% |
| Q2 2025 | $172.1M | +2.5% |
| Q1 2025 | $162.6M | -2.8% |
| Q4 2024 | $209.3M | -9.5% |
CRCT's revenue is recovering but still below its 2021 peak: $189M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +4.7 points |
| Q2 2026 | 30% | +13 points |
| Q1 2026 | 14% | -3.7 points |
| Q4 2025 | 6.8% | +0.2 points |
| Q3 2025 | 13% | +7 points |
| Q2 2025 | 17% | +1.7 points |
| Q1 2025 | 18% | +3 points |
| Q4 2024 | 6.6% | -0.5 points |
CRCT's operating margin was 18% last quarter, up 4.7 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CRCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CRCT on profitability, with a higher operating margin.
CRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.7M | +16% |
| Q2 2026 | $50.4M | +39% |
| Q1 2026 | $26.9M | -56% |
| Q4 2025 | $82.4M | -20% |
| Q3 2025 | $20.5M | -71% |
| Q2 2025 | $36.2M | +3.4% |
| Q1 2025 | $61.2M | +7.9% |
| Q4 2024 | $103.1M | +12% |
CRCT still generates free cash flow, though less than at its 2022 peak: $183M over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CRCT on cash flow, with more consistent year-over-year improvement.
CRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +1.7M shares |
| 1 year | -1.2% | -2.5M shares |
| 3 years | -3.5% | -7.6M shares |
| 5 years | -5.1% | -11.5M shares |
| Available history | -3.9% | -8.6M shares |
CRCT has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.9M |
| Q2 2026 | $7.5M |
| Q1 2026 | $12.3M |
| Q4 2025 | $5.7M |
| Q3 2025 | $2.4M |
| Q2 2025 | $4.7M |
| Q1 2025 | $12M |
| Q4 2024 | $8M |
CRCT spent $31M buying back its own shares over the past year, up 16% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CRCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -2.7x | Net Cash |
| Q1 2025 | -2.3x | Net Cash |
| Q4 2024 | -2.2x | Net Cash |
CRCT has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.4 | Overbought |
| Stochastic | 74.8 | Neutral |
CRCT's weekly RSI is 76 (overbought) and its Stochastic is 75 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CRCT PE vs Technology Sector
| Metric | CRCT | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 28x | 32% below |
| PE % | 37 | 41 | 4 pts below |
CRCT has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.89 | 23% above |
| 20 week MA | $5.88 | 45% above |
| 50 week MA | $5.01 | 70% above |
| 100 week MA | $5.31 | 60% above |
| 200 week MA | $6.52 | 30% above |
CRCT has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
CRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.0 | $23.5 | +30% |
| 2022 | $23.5 | $10.1 | -57% |
| 2023 | $10.1 | $6.59 | -35% |
| 2024 | $6.59 | $5.75 | -13% |
| 2025 | $5.75 | $5.04 | -12% |
| 2026 YTD | $5.04 | $8.50 | +69% |
CRCT has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.